Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
04:05pm, Monday, 02'nd Aug 2021
BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial r
SA Marketplace 2021 Top Idea Contest: Mid-Year Update
02:57pm, Friday, 23'rd Jul 2021
At the mid-year mark, our contributors give updates on their picks.
Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
11:38am, Tuesday, 20'th Jul 2021
The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human pap
Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
04:05pm, Tuesday, 25'th May 2021
BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virt
Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
09:00am, Wednesday, 05'th May 2021
BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approxima
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
04:05pm, Thursday, 29'th Apr 2021
BURLINGAME, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
08:30am, Thursday, 25'th Mar 2021
BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial
Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
08:30am, Friday, 05'th Mar 2021
BURLINGAME, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will parti
The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More
02:17pm, Saturday, 20'th Feb 2021
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week
Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
04:10pm, Wednesday, 17'th Feb 2021
BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced
Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today
02:53pm, Friday, 12'th Feb 2021
Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinica
Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
09:00am, Friday, 12'th Feb 2021
BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offe
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
04:01pm, Thursday, 11'th Feb 2021
BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten publ
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
07:30am, Thursday, 04'th Feb 2021
Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory
